Copyright
©The Author(s) 2020.
World J Clin Oncol. Mar 24, 2020; 11(3): 143-151
Published online Mar 24, 2020. doi: 10.5306/wjco.v11.i3.143
Published online Mar 24, 2020. doi: 10.5306/wjco.v11.i3.143
Table 1 Patient and disease characteristics
Characteristics | Pertuzumab usage | Total (n = 304) | P value | |
Yes (n = 50) | No (n = 254) | |||
Age at MBC diagnosis | 0.0133 | |||
Mean ± SD | 54.5 ± 11.64 | 58.9 ± 11.53 | 58.1 ± 11.65 | |
Range | 32–79 | 23–95 | 23–95 | |
Race, n (%) | 0.0003 | |||
Chinese | 29 (58.0) | 167 (65.7) | 196 (64.5) | |
Malay | 4 (8.00) | 57 (22.4) | 61 (9.21) | |
Indian | 5 (10.0) | 14 (5.51) | 19 (6.25) | |
Others | 12 (24.0) | 16 (6.30) | 28 (20.1) | |
Hormone receptor status, n (%) | ||||
ER positive | 32 (64.0) | 125 (49.2) | 157 (51.6) | 0.0638 |
PR positive | 18 (36.0) | 82 (32.2) | 102 (33.6) | 0.3264 |
Grade, n (%) | 0.8160 | |||
Grade 1 | 0 (0.00) | 3 (1.83) | 3 (1.515) | |
Grade 2 | 8 (23.53) | 47 (28.7) | 55 (27.8) | |
Grade 3 | 26 (76.5) | 114 (69.5) | 140 (70.7) | |
Histology, n (%) | 0.0899 | |||
Invasive ductal carcinoma | 48 (96.0) | 220 (86.6) | 268 (88.2) | |
Others | 2 (4.00) | 34 (13.4) | 36 (11.8) | |
Site of metastases, n (%) | ||||
Brain | 6 (12.0) | 17 (6.69) | 23 (7.57) | 0.2369 |
Lung | 18 (36.0) | 115 (45.3) | 133 (43.8) | 0.2754 |
Liver | 22 (44.0 | 98 (38.6) | 120 (39.5) | 0.5276 |
Bone | 30 (60.0) | 137 (53.9) | 167 (54.9) | 0.4425 |
Other | 16 (32.0) | 94 (37.0) | 110 (36.2) | 0.5249 |
Follow-up duration (yr) | 0.8511 | |||
Median (IQR) | 20.6 (21.6) | 22.5 (29.5) | 21.5 (27.8) | |
Range | 1–74 | 0–92 | 0–92 |
- Citation: Rahardja S, Tan RYC, Sultana R, Leong FL, Lim EH. Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience. World J Clin Oncol 2020; 11(3): 143-151
- URL: https://www.wjgnet.com/2218-4333/full/v11/i3/143.htm
- DOI: https://dx.doi.org/10.5306/wjco.v11.i3.143